The University of California, San Diego (UCSD) is currently recruiting participants for six clinical trials exploring the therapeutic potential of cannabis across various medical conditions.
These studies aim to deepen our understanding of cannabis’s effects on pain relief, HIV treatment, neuropathic pain, and complex regional pain syndrome (CRPS). Information on these six studies can be found below.
Brain Mechanisms Supporting Cannabis-Induced Pain Relief
This pilot study seeks to identify the neural mechanisms by which vaporized cannabis alleviates acute pain. Participants aged 21 to 65 will undergo functional MRI scans to assess changes in cerebral blood flow following cannabis administration and exposure to noxious heat stimuli. The study began in May 2021 and is expected to conclude around March 2027.
Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity
Focusing on individuals with HIV, this study examines whether cannabis use affects antiretroviral therapy (ART) drug concentrations, mood, and cognitive function. Phase 1 involves assessing 120 participants to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, 40 participants will receive cannabis or a placebo to examine its acute effects on ART drug concentrations. The study started in February 2021 and is anticipated to complete around April 2025.
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
This study investigates how cannabis use influences cognitive behaviors and the endocannabinoid system in individuals with HIV. Participants aged 18 to 65 with infrequent cannabis use will be randomized to receive a 5-day course of either THC, CBD, or a placebo. The study aims to determine the effects of these cannabinoids on decision-making, response inhibition, and other cognitive functions. Commencing in May 2023, the study is projected to conclude by January 2026.
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
This trial explores how cannabinoids like THC and CBD affect the gut microbiome and neuroinflammation in people with and without HIV. In a randomized, cross-over design, 50 participants with HIV and 50 without will receive 14-day courses of oral THC and CBD. Researchers aim to determine if these cannabinoids reduce inflammation and improve gut function. The study began in September 2023 and is expected to complete around October 2027.
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
Targeting veterans with chronic neuropathic pain (CNP), this randomized phase II trial evaluates the efficacy of cannabis constituents—THC, CBD, and their combination—compared to a placebo. The study plans to enroll 320 veterans aged 21 and older who meet diagnostic criteria for high-impact CNP and are not current cannabis users. Initiated in June 2023, the trial is slated to conclude by June 2027.
Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome
This study aims to determine the potential effects and mechanisms of a high-CBD cannabis extract on pain relief in individuals with complex regional pain syndrome (CRPS). Participants aged 21 to 75 will undergo a six-week treatment period followed by a two-week follow-up. The trial began in June 2024 and is expected to complete around June 2029.
These clinical trials reflect UCSD’s commitment to advancing medical research on cannabis and its potential therapeutic applications. Individuals interested in participating or seeking more information can visit UCSD’s clinical trials website.
